KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?

KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?

KRAS genotyping is mandatory in metastatic colorectal cancer treatment prior to undertaking antiepidermal growth factor receptor (EGFR) monoclonal antibody therapy. BRAF V600E mutation is often present in colorectal carcinoma with CpG island methylator phenotype and microsatellite instability. Curre...

Full description

Bibliographic Details
Main Authors:	Nicolas Piton, Francesco Borrini, Antonio Bolognese, Aude Lamy, Jean-Christophe Sabourin
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	Gastroenterology Research and Practice
Online Access:	http://dx.doi.org/10.1155/2015/753903

Similar Items

The Possible Therapeutic Strategy for Colorectal Cancer with KRAS/BRAF Mutations
by: Jing-Jung Chen, et al.
Published: (2012)

Molecular understanding of KRAS- and BRAF-mutated colorectal cancers
by: Lundberg, Ida
Published: (2017)

ANALYSIS OF MUTATIONS IN KRAS AND BRAF GENES IN COLORECTAL CANCER IN RUSSIAN PATIENTS
by: E. E. Pisareva, et al.
Published: (2016-07-01)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
by: Daeyoun David Won, et al.
Published: (2017-06-01)

Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study
by: Joon-Hyop Lee, et al.
Published: (2019-01-01)

KRAS, p53 and BRAF Gene Mutations and Aneuploidy in Sporadic Colorectal Cancer Progression
by: Daniele Calistri, et al.
Published: (2006-01-01)

KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
by: Abolfazl Yari, et al.
Published: (2020-06-01)

Mitochondrial Respiration in <i>KRAS</i> and <i>BRAF</i> Mutated Colorectal Tumors and Polyps
by: Egle Rebane-Klemm, et al.
Published: (2020-03-01)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
by: Qiwei Yang, et al.
Published: (2018-10-01)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
by: Sally Temraz, et al.
Published: (2015-09-01)

Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis
by: Snehangshu Kundu, et al.
Published: (2021-07-01)

Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
by: Hutton, Josiah Ewing
Published: (2016)

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
by: Claire Franczak, et al.
Published: (2020-01-01)

Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations
by: Raphaela Fritsche-Guenther, et al.
Published: (2018-06-01)

KRAS, NRAS, and BRAF Mutation Pattern in Metastatic Colorectal Cancer: A Study from Northwest Iran
by: Roya Dolatkhah, et al.
Published: (2019-08-01)

Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A case report supporting the concept of tumoral heterogeneity
by: Pegah Larki, et al.
Published: (2017-05-01)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
by: S. Gattenlöhner, et al.
Published: (2009-01-01)

KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
by: Chen Mao, et al.
Published: (2012-01-01)

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component
by: Xiaodong Li, et al.
Published: (2020-05-01)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
by: Sergiu Pasca, et al.
Published: (2019-10-01)

KRAS and BRAF Mutation in Borderline Epithelial Type Ovarian Tumor
by: Dodi Suardi
Published: (2013-04-01)

<it>BRAF</it>, <it>KRAS </it>and <it>PIK3CA </it>mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?
by: Schmitt Fernando, et al.
Published: (2008-09-01)

Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study
by: Hooria Momenzadeh, et al.
Published: (2018-01-01)

One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status.
by: Robin Myte, et al.
Published: (2018-01-01)

Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer
by: Luca Reggiani Bonetti, et al.
Published: (2018-01-01)

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
by: Suhail Al-Salam, et al.
Published: (2020-01-01)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
by: Omer Bayrak, et al.
Published: (2014-08-01)

KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia.
by: Miriam Juárez, et al.
Published: (2017-01-01)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring V600E Mutation
by: Jeong-Hwa Kwon, et al.
Published: (2018-05-01)

Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
by: Loretta László, et al.
Published: (2021-03-01)

INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO
by: V. P. Shubin, et al.
Published: (2020-10-01)

Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study.
by: Jenny Brändstedt, et al.
Published: (2014-01-01)

Evaluation of mutations in KRAS and BRAF genes in Iranian population with diffuse gastric cancer
by: M. Saneipour, et al.
Published: (2019-07-01)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction.
by: Reina E Ito, et al.
Published: (2021-01-01)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
by: Valérie Costes, et al.
Published: (2013-03-01)

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
by: Halfdan Sorbye, et al.
Published: (2015-01-01)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
by: Kristine Aasebø, et al.
Published: (2020-02-01)

Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.
by: Francesco Damin, et al.
Published: (2018-01-01)

Dasatinib Reduces Cetuximab Resistance in KRAS and BRAF Mutated Colorectal Carcinoma Cells Through Inhibiting Matrix-Dependent Cell Migration
by: CHIU, HSIANG-LING, et al.
Published: (2019)

APC, BRAF and KRAS mutations, and MLH1, MGMT and CDKN2A expression analysis in Nepalese colorectal cancer patients. : -
by: Nourizadeh, Alireza
Published: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lndi4m14jh0pginl8me1nieeq3